Several inhibitors of KRAS(G12C) have entered clinical trials, including AMG510 (Amgen), which is being evaluated for the treatment of non-small cell lung cancer, colorectal cancer (CRC), and other solid tumors harboring this mutation.15 To determine whether autophagy induced by mutant KRAS depends on KRAS activation in our system, we tested the effect of AMG510 on LC3-II. Here, KRAS is linked to colorectal carcinoma.